Local Ablative Therapy Shows Promise in Oligoprogressive NSCLC
Summary
Local ablative therapy alone is linked to a median 11 months of progression-free survival in oligoprogressive non-small cell lung cancer after durvalumab. Medscape News UK
Description from Medscape.
Who is covering this
-
Local Ablative Therapy Shows Promise in Oligoprogressive NSCLC
Local ablative therapy alone is linked to a median 11 months of progression-free survival in oligoprogressive non-small cell lung cancer after durvalumab. Medscape News UK
Comments
Comments need JavaScript.